Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Rated Buy in New Coverage at UBS Group

Posted by George Bondi on Oct 15th, 2026

Equities researchers at UBS Group assumed coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) in a research note issued on Thursday. The firm set a “buy” rating and a $109.00 price target on the biotechnology company’s stock. UBS Group’s price target indicates a potential upside of 86.53% from the stock’s current price.

Several other research firms also recently weighed in on ARWR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 17th. The Goldman Sachs Group initiated coverage on Arrowhead Pharmaceuticals in a research note on Thursday, September 24th. They issued a “neutral” rating and a $74.00 price objective for the company. Morgan Stanley upped their target price on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. HC Wainwright reiterated a “buy” rating and issued a $120.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Eleven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $99.07.

Get Our Latest Analysis on Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR traded up $0.07 during trading hours on Thursday, hitting $58.44. 855,724 shares of the company were exchanged, compared to its average volume of 2,286,365. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. Arrowhead Pharmaceuticals has a 52-week low of $36.57 and a 52-week high of $95.49. The stock has a market capitalization of $8.23 billion, a price-to-earnings ratio of -26.01 and a beta of 1.29. The company’s 50 day moving average price is $76.71 and its 200-day moving average price is $75.99.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. The company had revenue of $75.25 million during the quarter, compared to analysts’ expectations of $44.17 million. During the same period in the prior year, the business posted ($1.26) EPS. The company’s quarterly revenue was up 171.0% on a year-over-year basis. As a group, research analysts forecast that Arrowhead Pharmaceuticals will post -3.62 earnings per share for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, Director Michael S. Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares in the company, valued at $9,730,370.70. The trade was a 9.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the transaction, the director owned 31,600 shares in the company, valued at $2,747,936. This represents a 5.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at about $1,208,838,000. Baker BROS. Advisors LP increased its stake in Arrowhead Pharmaceuticals by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 2,175,645 shares of the biotechnology company’s stock worth $144,441,000 after buying an additional 504,883 shares in the last quarter. Siren L.L.C. raised its holdings in shares of Arrowhead Pharmaceuticals by 7.7% during the first quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company’s stock valued at $101,290,000 after acquiring an additional 115,000 shares during the last quarter. Jupiter Topco LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the second quarter valued at approximately $99,623,000. Finally, Janus Henderson Group PLC increased its position in shares of Arrowhead Pharmaceuticals by 12.2% during the first quarter. Janus Henderson Group PLC now owns 1,436,990 shares of the biotechnology company’s stock worth $90,119,000 after purchasing an additional 156,544 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

More Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

Positive Sentiment: Positive ARO-MAPT results: Interim Phase 1/2a data showed up to a 73% reduction in tau, a protein associated with Alzheimer’s disease, with reductions described as deep and durable in healthy volunteers. The company said the results provide the first clinical validation of its TRiM platform’s ability to deliver siRNA across the blood-brain barrier and reduce a target gene in the brain. Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data
Positive Sentiment: Alzheimer’s program strengthens the pipeline: The reported ability to cross the blood-brain barrier could support ARO-MAPT and other programs using Arrowhead’s TRiM CNS delivery platform. Coverage highlighted the potential significance of the early-stage data, although the study remains investigational and was conducted in healthy volunteers. Arrowhead Reports Positive Phase 1/2a Data for Alzheimer’s Candidate ARO-MAPT
Positive Sentiment: Analysts reaffirm bullish views: Chardan Capital reiterated its “buy” rating and set a $115 price target, while HC Wainwright also reaffirmed “buy” with a $120 target. Both targets imply substantial upside from recent trading levels, providing additional support for investor sentiment.
Neutral Sentiment: Important clinical caveat: The ARO-MAPT findings are interim Phase 1/2a results and primarily demonstrate biomarker reduction and delivery, not yet proof that the therapy improves cognition or slows Alzheimer’s disease. Further clinical testing will be needed to establish efficacy and safety. Arrowhead Discusses ARO-MAPT Interim Results and TRiM CNS Delivery
Neutral Sentiment: Some coverage noted differing analyst views on healthcare stocks, including Arrowhead, indicating that valuation and execution risks remain despite the favorable ARO-MAPT update.

About Arrowhead Pharmaceuticals

(Get Free Report)

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.